Navigation Links
ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
Date:10/14/2008

- Conference Call to Discuss Results to Be Held at 9:00 A.M. -

EXTON, Pa., Oct. 14 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2008 are expected to be released on Wednesday, October 29, 2008 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the third quarter financial results for 2008 and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until November 15, 2008. To participate in the conference call, please dial 877-366-0713 (domestic) and 302-607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma to Present at Three October Healthcare Conferences
2. ViroPharma to Present at Three September Healthcare Conferences
3. ViroPharma To Acquire Lev Pharmaceuticals
4. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
5. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
6. ViroPharma to Present at Two Upcoming Healthcare Conferences
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
9. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
10. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
11. ViroPharma to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a nationwide ... pleased to announce their ranking as one of the top 5000 companies listed on ... companies across the nation. , “It is truly an honor to be recognized as ...
(Date:8/27/2015)... Aug. 27, 2015 /PRNewswire/ - Portage Biotech Inc. ... and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced ... I study of BHV-0223, a glutamate modulating agent. ... BHV-0223 and recently obtained clearance from the U.S. ... human testing. Portage holds 54% equity interest in ...
(Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
(Date:8/27/2015)... HUYA Bioscience International (HUYA) today announced the sponsorship ... of HTLV-1, held this week at the University of ... Society is to promote research on HTLV-1 and HTLV-1-associated ... and research related to these fields to advance science, ... proud to support this prestigious conference," said Mireille ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... , , --2Q09 ... Controlling Interest was $13.2 million or , ... $0.17 per Diluted Share--, -- Company Generates ... Inc. (NYSE: AOB ), ("the Company" or,"AOBO"), a pharmaceutical company dedicated to ...
... , , SALEM, N.H., Aug. 7 ALPCO Diagnostics ... c tin EL I SA kit ... it is a departure from other methods for determining mouse HMW adiponectin ... Dr. Hiroyuki Ebinuma of the Tsukuba Research Institute in the journal Clinica ...
... , PASADENA, Calif., Aug. 6 AutoImmune Inc. ... or $0.01 per share basic and diluted, for the three months ... or $0.01 per share basic and diluted, for the three months ... 2009, the net loss was $256,000, or $0.02 per share basic ...
Cached Biology Technology:American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 2American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 3American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 4American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 5American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 6American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 7American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 8ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA 2AutoImmune Inc. Reports 2009 Second Quarter Financial Results 2AutoImmune Inc. Reports 2009 Second Quarter Financial Results 3AutoImmune Inc. Reports 2009 Second Quarter Financial Results 4AutoImmune Inc. Reports 2009 Second Quarter Financial Results 5
(Date:8/5/2015)... 2015 The biosensors market is proving highly ... into newer sectors, and development of devices resulting in ... has seen the entry of multiple participants each year ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... the Global Biosensors Market ( http://www.frost.com/nee9 ), finds ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the second ... Second quarter contract revenue of $ 85.2 million, ... margins of 26 % , Second quarter ... from royalties in the current quarter , Operating ... pleased to present another strong financial quarter, with all our divisions ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... semi-decayed vegetation matter, has been used by commercial growers ... century. Peat is added to potting soil to help ... for peat grew, acres of peat bogs were being ... of extracting peat from wetlands are mounting. And as ...
... This is the conclusion of a study which has analyzed the ... 14 years. The decrease in this activity and the fall in ... 10%) are the reasons why the "war", in the sense of ... Researchers from the Mediterranean Institute for Advanced Studies (IMEDEA-CSIC) ...
... This release is available in German . ... restoration and maintenance of the Earth,s multi-trillion dollar ecosystems - ... can have a key role in countering climate change and ... of a new climate issues update by The Economics of ...
Cached Biology News:For peat's sake: Alternative growing media 2The war against wildlife comes to an end in Southern Europe 2Time to tap climate change-combating potential of the world's ecosystems 2Time to tap climate change-combating potential of the world's ecosystems 3Time to tap climate change-combating potential of the world's ecosystems 4Time to tap climate change-combating potential of the world's ecosystems 5
Affinity Purified Anti-Human NP-1...
Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... culture supernates and serum. Each kit contains ... fifteen 96-well plates, provided that the following ...
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
Biology Products: